Association between antipsychotic-induced elevation of liver enzymes and weight gain: A prospective study

Journal of Clinical Psychopharmacology

Volumn 26, Issue 5, 2006, Pages 500-503

  Rettenbacher, Maria A ^a   Baumgartner, Susanne ^a   Eder Ischia, Ursula ^a   Edlinger, Monika ^a   Graziadei, Ivo ^a   Hofer, Alex ^a   Huber, Regina ^a   Hummer, Martina ^a   Kemmler, Georg ^a   Weiss, Elisabeth ^a   Fleischhacker, W Wolfgang ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMISULPRIDE; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CLOZAPINE; GAMMA GLUTAMYLTRANSFERASE; LIVER ENZYME; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; EOSINOPHILIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 33748752683     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000236654.85791.ae     Document Type: Article

References (24)

1. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull. 1997;23(4):567-582.
2. Dumortier G, Cabaret W, Stamatiadis L, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale. 2002;28:542-551.
3. Gärtner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology. 1989;99(suppl):S97-S100.
4. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal antiinflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis. 2002;22(2):169-183.
5. Pae CU, Lim HK, Kim TS, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol. 2005;20:173-176.
6. Retnakaran R, Hanley A, Connelly P, et al. Ethinicity modifies the effect of obesity on insulin resistance in pregnancy: a comparison of Asian, South Asian and Caucasian women. J Clin Endocrinol Metab. 2005;91(1):93-97.
7. Hummer M, Kurz M, Kurzthaler I, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17(4):314-317.
8. Holtmann M, Kopf D, Mayer M, et al. Risperidone-associated steatohepatis and excessive weight gain. Pharmacopsychiatry. 2003;36(5):206-207.
9. Krebs S, Dormann H, Muth-Selbach U, et al. Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol. 2001;13:67-69.
10. Whitworth AB, Liensberger D, Fleischhacker WW. Transient increase of liver enzymes induced by risperidone: two case reports. J Clin Psychopharmacol. 1999;19(5):475-476.
11. Benazzi F. Risperidone-induced hepatotoxicity. Pharmacopsychiatry. 1998;31(6):241.
12. Kinon BJ, Kaiser CJ, et al. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacology. 2005;25(3):255-258.
13. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158:1719-1722.
14. Sennello JA, Fayad R, Morris AM, et al. Regulation of T cell-mediated hepatic inflammation by adipenctin and leptin. Endocrinology. 2005;146:2157-2164.
15. Mizuhara H, O'Neill E, Seki N. T-cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin-6. J Exp Med. 1994;179:1529-1537.
16. Orange JS, Salazar-Mather TP, Opal SM, et al. Mechanisms for virus-induced liver disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol. 1997;71:9248-9258.
17. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339:1217-1227.
18. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-2250.
19. Tilg H, Diehl AM. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med. 2000;343:1467-1476.
20. Boyer JL. Mechanisms of chlorpromazine cholestosis: hypersensitivity on toxic metabolite? Gastroenterology. 1978;74:1331-1333.
21. Kaplowitz N, Aw TY, Simon FR, et al. Drug-induced hepatotoxicity. Ann Intern Med. 1986;104:826-839.
22. Akerboom T, Schneider I, vom Dahl S, et al. Cholestasis and changes of portal pressure caused by chlorpromazine in the perfused rat liver. Hepatology. 1991;13:216-221.
23. Johnson EI, Lanford RE, Solomon K. Chlorpromazine, eosinophilia and hepatotoxicity. Va Med. 1979;106(9):683-684.
24. Dölle H. Erkrankungen durch Arzneimittel. Stuttgart: Thieme-Verlag; 1978.